Medication leaflets

Active substance

Results for the substance siponimod

4 results

About this active substance

Siponimod is a selective sphingosine-1-phosphate (S1P) receptor modulator used in the treatment of secondary progressive multiple sclerosis (SPMS) with active disease. It works by retaining lymphocytes in lymph nodes, reducing inflammation and preventing damage to the central nervous system.

Siponimod is administered orally, usually once daily, with the dose adjusted based on the patient's CYP2C9 genotype, as its metabolism is influenced by this enzyme. It is indicated for patients with active SPMS, characterized by relapses or confirmed disability progression.

Common side effects include headache, hypertension, elevated liver enzymes, and bradycardia. In rare cases, severe adverse reactions such as macular edema or serious infections may occur. Regular monitoring of cardiac function, vision, and liver parameters is essential during treatment.

Siponimod represents an innovative therapeutic option for patients with secondary progressive multiple sclerosis, helping to slow disease progression and improve quality of life.